Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

Article  PubMed  Google Scholar 

Cabrera AR, Lee WR. Hypofractionation for clinically localized prostate cancer. Semin Radiat Oncol. 2013;23:191–7.

Article  PubMed  Google Scholar 

Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol. 2019;201:528–34.

Article  PubMed  Google Scholar 

Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325–32.

Article  PubMed  PubMed Central  Google Scholar 

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–60.

Article  PubMed  PubMed Central  Google Scholar 

Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884–90.

Article  CAS  PubMed  Google Scholar 

Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial. J Clin Oncol. 2017;35:1891–7.

Article  CAS  PubMed  Google Scholar 

Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1061–9.

Article  PubMed  Google Scholar 

Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018;36:2943–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860–8.

Article  PubMed  PubMed Central  Google Scholar 

Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, et al. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017;2:249–58.

Article  PubMed  PubMed Central  Google Scholar 

Stokes WA, Kavanagh BD, Raben D, Pugh TJ. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract. Radiat Oncol. 2017;7:270–8.

Google Scholar 

Jaworski L, Dominello MM, Heimburger DK, Mancini BR Jr, Boike TP, Schipper M, et al. Contemporary practice patterns for intact and post-operative prostate cancer: results from a statewide collaborative. Int J Radiat Oncol Biol Phys. 2019;105:E282.

Article  Google Scholar 

Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. Intensity modulated radiation therapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69:S10.

Article  PubMed  PubMed Central  Google Scholar 

Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241–9.

Article  CAS  PubMed  Google Scholar 

Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2004;59:267–84.

Article  PubMed  Google Scholar 

Fenoglietto P, Laliberte B, Allaw A, Ailleres N, Idri K, Hay MH, et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother Oncol. 2008;88:77–87.

Article  PubMed  Google Scholar 

Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.

Article  CAS  PubMed  Google Scholar 

Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85:101–5.

Article  PubMed  Google Scholar 

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.

Article  PubMed  Google Scholar 

Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received. Eur Urol. 2020;77:320–30.

Article  PubMed  Google Scholar 

Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–9.

Article  PubMed  Google Scholar 

Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685–91.

Article  PubMed  Google Scholar 

Buckey C, Swanson G, Stathakis S, Papanikolaou N. Dosimetric comparison between 3D conformal and intensity-modulated radiation therapy for prostate cancer. J Radiother Pr. 2010;9:77–85.

Article  Google Scholar 

Kneebone A, Gebski V, Hogendoorn N, Turner S. A randomized trial evaluating rigid immobilization for pelvic irradiation. Int J Radiat Oncol Biol Phys. 2003;56:1105–11.

Article  PubMed  Google Scholar 

Lee JA, Kim CY, Park YJ, Yoon WS, Lee NK, Yang DS. Interfractional variability in intensity-modulated radiotherapy of prostate cancer with or without thermoplastic pelvic immobilization. Strahlenther Onkol. 2014;190:94–9.

Article  CAS  PubMed  Google Scholar 

Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036–46.

Article  PubMed  Google Scholar 

Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005;62:706–13.

Article  PubMed  Google Scholar 

Yoo S, Wu QJ, Lee WR, Yin F-F. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol Phys. 2010;76:935–42.

Article  PubMed  Google Scholar 

Crijns W, Budiharto T, Defraene G, Verstraete J, Depuydt T, Haustermans K, et al. IMRT-based optimization approaches for volumetric modulated single arc radiotherapy planning. Radiother Oncol. 2010;95:149–52.

Article  PubMed  Google Scholar 

Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol. 2003;21:200–8.

Article  PubMed  Google Scholar 

Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, et al. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiother Oncol. 2019;135:19–24.

Article  PubMed  PubMed Central  Google Scholar 

Ghadjar P, Zelefsky MJ, Spratt DE. Munck af Rosenschöld P, Oh JH, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88:339–44.

Article  PubMed  PubMed Central  Google Scholar 

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76:S3–9.

Article  PubMed  PubMed Central  Google Scholar 

Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76:S123–9.

Article  PubMed  PubMed Central  Google Scholar 

Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose–volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76:S116–22.

Article  PubMed  PubMed Central  Google Scholar 

Roach M 3rd, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010;76:S130–4.

Article  PubMed  PubMed Central